Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 709756, 11 pages
http://dx.doi.org/10.1155/2014/709756
Research Article

Serum Lipids, Apolipoproteins, and Mortality among Coronary Artery Disease Patients

1Guangdong Provincial Key Laboratory of Food, Nutrition and Health, Department of Nutrition, School of Public Health, Sun Yat-sen University, No. 74 Zhongshan Road 2, Guangzhou, Guangdong 510080, China
2Chronic Disease Epidemiology Laboratory, Pennington Biomedical Research Center, 6400 Perkins Road, Baton Rouge, LA 70808, USA
3Department of Cardiology, General Hospital of Guangzhou Military Command of People's Liberation Army, Guangdong 510010, China

Received 24 February 2014; Revised 6 May 2014; Accepted 16 May 2014; Published 29 May 2014

Academic Editor: Claudia Slimings

Copyright © 2014 Ding Ding et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Yusuf, S. Reddy, S. Ôunpuu, and S. Anand, “Global burden of cardiovascular diseases—part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization,” Circulation, vol. 104, no. 22, pp. 2746–2753, 2001. View at Google Scholar · View at Scopus
  2. World Health Organization, Global Health Observatory (GHO): Raised Cholesterol, 2014, http://apps.who.int/gho/data/node.main.A884.
  3. J. Pekkanen, S. Linn, G. Heiss et al., “Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease,” The New England Journal of Medicine, vol. 322, no. 24, pp. 1700–1707, 1990. View at Google Scholar · View at Scopus
  4. W. P. Castelli, K. Anderson, P. W. F. Wilson, and D. Levy, “Lipids and risk of coronary heart disease. The Framingham study,” Annals of Epidemiology, vol. 2, no. 1-2, pp. 23–28, 1992. View at Google Scholar · View at Scopus
  5. S. M. Grundy, J. I. Cleeman, C. N. B. Merz et al., “Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines,” Circulation, vol. 110, no. 2, pp. 227–239, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. W. P. Castelli, R. J. Garrison, and P. W. F. Wilson, “Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham study,” The Journal of the American Medical Association, vol. 256, no. 20, pp. 2835–2838, 1986. View at Google Scholar · View at Scopus
  7. G. Hu, Y. Cui, P. Jousilahti et al., “Joint effect of high-density lipoprotein cholesterol and low-density lipoprotein cholesterol on the risk of coronary heart disease,” European Journal of Preventive Cardiology, vol. 20, no. 1, pp. 89–97, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. M. T. Cooney, A. Dudina, D. de Bacquer et al., “HDL cholesterol protects against cardiovascular disease in both genders, at all ages and at all levels of risk,” Atherosclerosis, vol. 206, no. 2, pp. 611–616, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. P. J. Barter, S. Nicholls, K. Rye, G. M. Anantharamaiah, M. Navab, and A. M. Fogelman, “Antiinflammatory properties of HDL,” Circulation Research, vol. 95, no. 8, pp. 764–772, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Benn, B. G. Nordestgaard, G. B. Jensen, and A. Tybjærg-Hansen, “Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B: the Copenhagen City heart study,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 3, pp. 661–670, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. P. M. Ridker, N. Rifai, N. R. Cook, G. Bradwin, and J. E. Buring, “Non-HDL cholesterol, apolipoproteins A-I and B 100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women,” The Journal of the American Medical Association, vol. 294, no. 3, pp. 326–333, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. G. Walldius, I. Jungner, I. Holme, A. H. Aastveit, W. Kolar, and E. Steiner, “High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study,” The Lancet, vol. 358, no. 9298, pp. 2026–2033, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. B. J. Ansell, M. Navab, S. Hama et al., “Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment,” Circulation, vol. 108, no. 22, pp. 2751–2756, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Besler, K. Heinrich, L. Rohrer et al., “Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease,” Journal of Clinical Investigation, vol. 121, no. 7, pp. 2693–2708, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. B. Shao, M. N. Oda, J. F. Oram, and J. W. Heinecke, “Myeloperoxidase: an inflammatory enzyme for generating dysfunctional high density lipoprotein,” Current Opinion in Cardiology, vol. 21, no. 4, pp. 322–328, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. S. C. Tao, Z. D. Huang, X. G. Wu et al., “CHD and its risk factors in the People's Republic of China,” International Journal of Epidemiology, vol. 18, supplement 1, pp. S159–S163, 1989. View at Google Scholar · View at Scopus
  17. W. Yang, J. Xiao, Z. Yang et al., “Serum lipids and lipoproteins in Chinese men and women,” Circulation, vol. 125, no. 18, pp. 2212–2221, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. F. Farzadfar, M. M. Finucane, G. Danaei et al., “National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3·0 million participants,” The Lancet, vol. 377, no. 9765, pp. 578–586, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. G. Yang, L. Kong, W. Zhao et al., “Emergence of chronic non-communicable diseases in China,” The Lancet, vol. 372, no. 9650, pp. 1697–1705, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. D. Ding, J. Qiu, X. Li et al., “Hyperglycemia and mortality among patients with coronary artery disease,” Diabetes Care, vol. 37, no. 2, pp. 546–554, 2014. View at Publisher · View at Google Scholar
  21. R. J. Gibbons, K. Chatterjee, J. Daley et al., “ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: executive summary and recommendations: a report of the American college of cardiology/American heart association task force on practice guidelines (committee on management of patients with chronic stable angina),” Circulation, vol. 99, no. 21, pp. 2829–2848, 1999. View at Google Scholar · View at Scopus
  22. E. Braunwald, E. M. Antman, J. W. Beasley et al., “ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: executive summary and recommendations: a report of the American college of cardiology/American heart association task force on practice guidelines (committee on the management of patients with unstable angina),” Circulation, vol. 102, no. 10, pp. 1193–1209, 2000. View at Google Scholar · View at Scopus
  23. B. Zhang, P. Wang, C. G. Chen et al., “Validation of an FFQ to estimate the intake of fatty acids using erythrocyte membrane fatty acids and multiple 3d dietary records,” Public Health Nutrition, vol. 13, no. 10, pp. 1546–1552, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. L. N. Kolonel, B. E. Henderson, J. H. Hankin et al., “A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics,” The American Journal of Epidemiology, vol. 151, no. 4, pp. 346–357, 2000. View at Google Scholar · View at Scopus
  25. “The World Health Organization MONICA project (monitoring trends and determinants in cardiovascular disease): a major international collaboration,” Journal of Clinical Epidemiology, vol. 41, no. 2, pp. 105–114, 1988. View at Scopus
  26. A. S. Levey, J. Coresh, T. Greene et al., “Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate,” Annals of Internal Medicine, vol. 145, no. 4, pp. 247–254, 2006. View at Google Scholar · View at Scopus
  27. E. Di Angelantonio, P. Gao, L. Pennells et al., “Lipid-related markers and cardiovascular disease prediction,” The Journal of the American Medical Association, vol. 307, no. 23, pp. 2499–2506, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. E. Di Angelantonio, N. Sarwar, P. Perry et al., “Major lipids, apolipoproteins, and risk of vascular disease,” The Journal of the American Medical Association, vol. 302, no. 18, pp. 1993–2000, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. P. Barter, A. M. Gotto, J. C. LaRosa et al., “HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events,” The New England Journal of Medicine, vol. 357, no. 13, pp. 1301–1310, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. M. J. Chapman, G. Assmann, J. C. Fruchart, J. Shepherd, and C. Sirtori, “Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid—a position paper developed by the European consensus panel on HDL-C,” Current Medical Research and Opinion, vol. 20, no. 8, pp. 1253–1268, 2004. View at Google Scholar · View at Scopus
  31. I. M. Singh, M. H. Shishehbor, and B. J. Ansell, “High-density lipoprotein as a therapeutic target: a systematic review,” The Journal of the American Medical Association, vol. 298, no. 7, pp. 786–798, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. D. Duffy and D. J. Rader, “Update on strategies to increase HDL quantity and function,” Nature Reviews Cardiology, vol. 6, no. 7, pp. 455–463, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. E. Angeloni, F. Paneni, U. Landmesser et al., “Lack of protective role of HDL-C in patients with coronary artery disease undergoing elective coronary artery bypass grafting,” European Heart Journal, vol. 34, no. 46, pp. 3557–3562, 2013. View at Publisher · View at Google Scholar
  34. C. Besler, T. F. Lüscher, and U. Landmesser, “Molecular mechanisms of vascular effects of High-density lipoprotein: alterations in cardiovascular disease,” EMBO Molecular Medicine, vol. 4, no. 4, pp. 251–268, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. C. Mineo, H. Deguchi, J. H. Griffin, and P. W. Shaul, “Endothelial and antithrombotic actions of HDL,” Circulation Research, vol. 98, no. 11, pp. 1352–1364, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. S. A. Sorrentino, C. Besler, L. Rohrer et al., “Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy,” Circulation, vol. 121, no. 1, pp. 110–122, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. G. G. Schwartz, A. G. Olsson, M. Abt et al., “Effects of dalcetrapib in patients with a recent acute coronary syndrome,” The New England Journal of Medicine, vol. 367, no. 22, pp. 2089–2099, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. T. F. Lüscher, S. Taddei, J. C. Kaski et al., “Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial,” European Heart Journal, vol. 33, no. 7, pp. 857–865, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. A. J. Moss, R. E. Goldstein, V. J. Marder et al., “Thrombogenic factors and recurrent coronary events,” Circulation, vol. 99, no. 19, pp. 2517–2522, 1999. View at Google Scholar · View at Scopus
  40. Q. Lu, G. Tian, Y. Zhang, M. Lu, X. Lin, and A. Ma, “Low HDL-C predicts risk and PCI outcomes in the Han Chinese population,” Atherosclerosis, vol. 226, no. 1, pp. 193–197, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. A. G. Olsson, G. G. Schwartz, M. Szarek et al., “High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial,” European Heart Journal, vol. 26, no. 9, pp. 890–896, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Parish, A. Offer, R. Clarke et al., “Lipids and lipoproteins and risk of different vascular events in the MRC/BHF heart protection study,” Circulation, vol. 125, no. 20, pp. 2469–2478, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. R. J. Simes, I. C. Marschner, D. Hunt et al., “Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?” Circulation, vol. 105, no. 10, pp. 1162–1169, 2002. View at Publisher · View at Google Scholar · View at Scopus